BRACKNELL, U.K. - July 30, 2001 - Quintiles Transnational Corp. (Nasdaq: QTRN) and Synigence PLC today announced an exclusive co-marketing agreement to electronically deliver healthcare information and services to general practitioners in the United Kingdom via Synigence's Clinnix Pro application.

The agreement builds on a relationship first started in October 1999 and will allow Synigence and Quintiles' Innovex commercialization unit to promote a wide range of e-business solutions to general practitioners in the U.K. via a secure network. Clinnix Pro currently is used by more than 11,000 GPs, and should be on more than half of all GP desktops in the U.K. by October.

Through Clinnix Pro, GPs can access a broad range of peer-reviewed health information, including news bulletins, patient advice and treatment guideline databases. In addition, GPs can transmit and receive secure e-mail directly from Clinnix Pro. Clinnix Pro's easy-to-navigate content and services are updated hourly and can be accessed instantly.

Innovex will use Clinnix Pro to help healthcare professionals obtain continuing medical education, participate in market research and access information about medicines, among other uses.

"We are delighted to have concluded this agreement with Quintiles, which is the leader in providing pharmaceutical development and commercialization services to healthcare organizations in the U.K. and worldwide," said Laurence Greetham, Chief Executive Officer of Synigence. "They have chosen us as a co-marketing partner in the belief that together we are best suited to attract the e-commerce and electronic promotional spend of companies seeking to market within the professional services sector in the U.K."

Quintiles Europe President Andrew Howden said: "With almost 80 percent of Clinnix Pro users accessing it three to 10 times a day, Clinnix Pro demonstrates a level of value to GPs. This offers a valuable channel for healthcare organizations to provide the information and services that healthcare professionals demand."

As part of the agreement between the two companies, Quintiles has made an investment in Synigence through the purchase of Synigence ordinary shares by Quintiles' PharmaBio Development group and cash for exclusivity rights related to the co-marketing agreement between the two companies.

About Synigence PLC and Clinnix Pro
Synigence is a multimedia and value-added services production company specializing in the healthcare market. Through the installation of Clinnix Pro on the desktop or servers of general practitioners, Synigence is forging a network for GPs that enables them to benefit from hourly delivery of free, peer-reviewed healthcare information, together with other high-quality services delivered through Clinnix Pro. This network provides the opportunity for the pharmaceutical industry and other healthcare organizations to deliver information and services to the U.K. GP community through Clinnix Pro.

About Quintiles Transnational, Innovex and PharmaBio Development
Quintiles Transnational is the world's leading provider of information, technology and services to bring new medicines to patients faster and improve healthcare. Headquartered near Research Triangle Park, North Carolina, Quintiles employs a global workforce of 18,000 in 39 countries. Quintiles Transnational is a member of the S&P 500 and Fortune 1000. For more information visit the company's web site at www.quintiles.com.

Innovex, the commercialization unit of Quintiles Transnational, is the world's leading commercial solutions provider. Innovex offers sales and marketing services designed to accelerate the success of pharmaceutical and biotech products. Since 1995, Innovex U.K. has created more than 50 sales teams across a wide range of therapeutic categories.

PharmaBio Development, the corporate ventures group of Quintiles Transnational, creates innovative partnering solutions to help life-science companies develop and market new products to improve human health.

Information in this press release contains "forward-looking statements" regarding Quintiles that involve risks and uncertainties that could cause actual results to differ materially, including without limitation, the risk that the market for our products and services will not grow as we expect, the risk that PharmaBio transactions will not generate revenues or profit at the rate or levels we anticipate, our ability to efficiently distribute backlog among therapeutic business units and match demand to resources, actual operating performance, the ability to maintain large client contracts or to enter into new contracts, changes in trends in the pharmaceutical industry, and the ability to operate successfully in new lines of business. Additional factors that could cause actual results to differ materially are discussed in the company's recent filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs. Statements in this release regarding Synigence and Quintiles have been made by their respective company under that company's sole responsibility.